Hodgkin's Lymphoma (Hodgkin Lymphoma, Hodgkin's Disease)
The terms Hodgkin's lymphoma, Hodgkin lymphoma and Hodgkin's disease are used interchangeably on this site
Hodgkin's Lymphoma or Hodgkin's Disease is a malignant (cancerous) growth of cells in
the lymph system.
Other lymphomas are called the Non-Hodgkin's Lymphomas.
A medical diagnosis or symptoms of Hodgkin's Lymphoma can be scary. Please read our Hodgkin lymphoma pages
for more information.
Dive Deeper
Information on Adult Hodgkin's Disease:
- Adult Hodgkin's Disease: Introduction
- Adult Hodgkin's Lymphoma: Diagnosis
- Hodgkin's Lymphoma: Treatment
- Adult Hodgkin's Lymphoma: Chemotherapy
- Hodgkin's Lymphoma: Resources
- Hodgkin's Disease - Incidence
For Information on Childhood Hodgkin's lymphoma:
Personal Experiences with Hodgkin's Disease:
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
